Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58


Outcomes of patients with bone metastases from differentiated thyroid cancer.

Califano I, Deutsch S, Löwenstein A, Cabezón C, Pitoia F.

Arch Endocrinol Metab. 2018 Feb;62(1):14-20. doi: 10.20945/2359-3997000000004.


Impact of historic histopathologic sample review on the risk of recurrence in patients with differentiated thyroid cancer.

Pitoia F, Jerkovich F, Urciuoli C, Falcón F, Lima AP.

Arch Endocrinol Metab. 2018 Apr 5;62(2):157-163. doi: 10.20945/2359-3997000000020. Print 2018 Mar-Apr.


Should Age at Diagnosis Be Included as an Additional Variable in the Risk of Recurrence Classification System in Patients with Differentiated Thyroid Cancer.

Pitoia F, Jerkovich F, Smulever A, Brenta G, Bueno F, Cross G.

Eur Thyroid J. 2017 Jul;6(3):160-166. doi: 10.1159/000453450. Epub 2017 Jan 7.


The "broken chair" in patients with differentiated thyroid cancer.

La Greca A, Pitoia F, Tuttle RM.

Endocrine. 2017 Aug;57(2):359-360. doi: 10.1007/s12020-017-1345-y. Epub 2017 Jun 14. No abstract available.


Effects of sample storage and diluents in the reliability of thyroglobulin measurement in the washout of fine needle aspirates.

Piotrkowski-Viale F, Reyes A, Dios A, Pitoia F, Lowenstein A, Glikman P.

Endocrine. 2017 Jun;56(3):504-508. doi: 10.1007/s12020-017-1294-5. Epub 2017 Apr 6.


Timing of multikinase inhibitor initiation in differentiated thyroid cancer.

Brose MS, Smit J, Lin CC, Pitoia F, Fellous M, DeSanctis Y, Schlumberger M, Tori M, Sugitani I.

Endocr Relat Cancer. 2017 May;24(5):237-242. doi: 10.1530/ERC-17-0016. Epub 2017 Mar 7.


Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation.

Schmidt A, Iglesias L, Klain M, Pitoia F, Schlumberger MJ.

Arch Endocrinol Metab. 2017 Jan-Feb;61(1):81-89. doi: 10.1590/2359-3997000000245. Epub 2017 Feb 13. Review.


Selective use of sorafenib in the treatment of thyroid cancer.

Pitoia F, Jerkovich F.

Drug Des Devel Ther. 2016 Mar 11;10:1119-31. doi: 10.2147/DDDT.S82972. eCollection 2016. Review.


Dynamic prediction of the risk of recurrence in patients over 60 years of age with differentiated thyroid carcinoma.

Morosán YJ, Parisi C, Urrutia MA, Rosmarin M, Schnitman M, Serrano L, Luciani W, Faingold C, Pitoia F, Brenta G.

Arch Endocrinol Metab. 2016 Aug;60(4):348-54. doi: 10.1590/2359-3997000000146. Epub 2016 Feb 23.


2015 American Thyroid Association Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer and Their Implementation in Various Care Settings.

Pitoia F, Miyauchi A.

Thyroid. 2016 Feb;26(2):319-21. doi: 10.1089/thy.2015.0530. Epub 2015 Dec 17. No abstract available.


Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer.

Pitoia F, Abelleira E, Jerkovich F, Urciuoli C, Cross G.

Arch Endocrinol Metab. 2015 Aug;59(4):347-50. doi: 10.1590/2359-3997000000059.


Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.

Pitoia F, Bueno F, Schmidt A, Lucas S, Cross G.

Arch Endocrinol Metab. 2015 Aug;59(4):343-6. doi: 10.1590/2359-3997000000057.


Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.

Pitoia F, Jerkovich F, Urciuoli C, Schmidt A, Abelleira E, Bueno F, Cross G, Tuttle RM.

Thyroid. 2015 Nov;25(11):1235-42. doi: 10.1089/thy.2015.0121. Epub 2015 Aug 6.


Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer.

Pitoia F, Abelleira E, Bueno F, Urciuoli C, Schmidt A, Niepomniszcze H.

Endocrine. 2015 Apr;48(3):894-901. doi: 10.1007/s12020-014-0416-6. Epub 2014 Sep 11.


[Thyroid dysfunction in adults infected by human immunodeficiency virus].

Abelleira E, De Cross GA, Pitoia F.

Medicina (B Aires). 2014;74(4):315-20. Review. Spanish.


Definition and management of radioactive iodine-refractory differentiated thyroid cancer.

Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, Pacini F.

Lancet Diabetes Endocrinol. 2014 May;2(5):356-8. doi: 10.1016/S2213-8587(13)70215-8. Epub 2014 Jan 30. No abstract available.


Response to sorafenib treatment in advanced metastatic thyroid cancer.

Pitoia F.

Arq Bras Endocrinol Metabol. 2014 Feb;58(1):37-41.

Supplemental Content

Loading ...
Support Center